A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.

The company blamed its troubles in part on the FDA's refusal to approve its drug-patch for chronic migraine sufferers, including the agency's inability to inspect its Fremont manufacturing facility because of Covid restrictions.